This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pellagatti, A. Articles by Boultwood, J. Search for Related Content PubMed PubMed Citation Articles by Pellagatti, A. Articles by Boultwood, J.

Gene Expression Profiling in Polycythemia Vera Using cDNA Microarray Technology¹

Leukaemia Research Fund Molecular Haematology Unit, Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford OX3 9DU [A. P., S. G., H. E., J. S. W., J. B.], and Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA [D. V., C. F. L.], United Kingdom

Polycythemia vera (PV) is a myeloproliferative disorder characterized by an increased proliferation of all three myeloid lineages. The molecular pathogenesis of PV is unknown. Using cDNA microarrays comprising 6000 human genes, we studied the gene expression profile of granulocytes obtained from 11 PV patients compared with granulocytes obtained from healthy individuals. We found that 147 genes were up-regulated by 2.5 fold in the majority of PV patients. Eleven of these 147 genes were up-regulated in all PV patients studied and may represent a molecular signature for this disorder. An increase in the expression of several protease inhibitors with affinity for proteases that promote apoptosis in neutrophils (e.g., cystatin F, secretory leukocyte protease inhibitor), as well as the up-regulation of a number of antiapoptotic and survival factors was found (e.g., adrenomedullin, p38 mitogen-activated protein kinase). We speculate that the deregulation of these factors may inhibit normal apoptosis and promote cell survival in the granulocytes of patients with PV. These PV-specific expression changes are likely to be biologically important in the pathophysiology of this disorder.

This article has been cited by other articles:

				D. V. Gnatenko, P. L. Perrotta, and W. F. Bahou Proteomic approaches to dissect platelet function: half the story Blood, December 15, 2006; 108(13): 3983 - 3991. [Abstract] [Full Text] [PDF]

				A. Pellagatti, M. Cazzola, A. A. N. Giagounidis, L. Malcovati, M. G. D. Porta, S. Killick, L. J. Campbell, L. Wang, C. F. Langford, C. Fidler, et al. Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype Blood, July 1, 2006; 108(1): 337 - 345. [Abstract] [Full Text] [PDF]

				R. Kralovics, S.-S. Teo, A. S. Buser, M. Brutsche, R. Tiedt, A. Tichelli, F. Passamonti, D. Pietra, M. Cazzola, and R. C. Skoda Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2 Blood, November 15, 2005; 106(10): 3374 - 3376. [Abstract] [Full Text] [PDF]

				J. Larghero, N. Gervais, B. Cassinat, J.-D. Rain, M.-H. Schlageter, R. A. Padua, C. Chomienne, and P. Rousselot Farnesyltransferase inhibitor tipifarnib (R115777) preferentially inhibits in vitro autonomous erythropoiesis of polycythemia vera patient cells Blood, May 1, 2005; 105(9): 3743 - 3745. [Abstract] [Full Text] [PDF]